SCHEMBL5350274

SCHEMBL5350274

COc1ccc(CCNC(=O)C2(c3ccccc3)CCCCC2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 2/20 0.77
CHRM3 P20309 2/20 0.77
SMN1; SMN2 Q16637 4/20 0.60
HTT P42858 1/20 0.60
CHRM1 P11229 1/20 0.57
FPR2 P25090 1/20 0.55
NPC1 O15118 1/20 0.54
GAA P10253 1/20 0.54
RAB9A P51151 1/20 0.54
TAAR1 Q96RJ0 1/20 0.54
PLAAT3 P53816 2/20 0.54
PLAAT5 Q96KN8 2/20 0.54
PLAAT2 Q9NWW9 2/20 0.54
PLAAT4 Q9UL19 2/20 0.54
PTPN1 P18031 1/20 0.54
CHRM2 P08172 1/20 0.53
LMNA P02545 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
ALDH1A1 P00352 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8747064 0.96 CHRM5 (0.79) CHRM5CHRM3SMN1; SMN2HTTCHRM1
SCHEMBL2467338 0.88 CHRM5 (0.74) CHRM5CHRM3SMN1; SMN2CHRM1FPR2
SCHEMBL989924 0.84 ALDH1A1 (0.70) CHRM5CHRM3SMN1; SMN2FPR2ALDH1A1
SCHEMBL2469026 0.84 CHRM5 (0.70) CHRM5CHRM3CHRM1NPC1RAB9A
SCHEMBL5350234 0.84 SMN1; SMN2 (0.64) CHRM5CHRM3SMN1; SMN2HTTNPC1
SCHEMBL2471145 0.83 CHRM5 (0.77) CHRM5CHRM3SMN1; SMN2CHRM1ALDH1A1
SCHEMBL13593900 0.82 CHRM5 (0.74) CHRM5CHRM3CHRM1PLAAT3PLAAT5
SCHEMBL989809 0.81 ALDH1A1 (0.77) CHRM5CHRM3SMN1; SMN2HTTFPR2
SCHEMBL13593903 0.81 CHRM5 (0.73) CHRM5CHRM3CHRM1FPR2TAAR1
SCHEMBL2473049 0.81 CHRM5 (0.73) CHRM5CHRM3SMN1; SMN2CHRM1FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNN3, KCNQ5 CHRM5 528/4885CHRM3 481/4885SMN1; SMN2 4281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.